Aarti Pharmalabs Ltd (AARTIPHARM) — shareholding pattern, promoter holding, financials and share price
About Aarti Pharmalabs Ltd (AARTIPHARM)
Aarti Pharmalabs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AARTIPHARM and on the BSE under scrip code 543748. Its ISIN is INE0LRU01027.
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals [1]
Aarti Pharmalabs is a vertically integrated Indian manufacturer of generic APIs, intermediates, HPAPIs and xanthine derivatives, and a growing small-molecule CDMO/CMO provider with three USFDA-approved units, seven manufacturing sites and a focus on regulated markets across the USA, EU, Japan and ROW.
Aarti Pharmalabs is the largest Indian manufacturer of Xanthine derivatives with ~15–20% global share today and is building incremental capacity from 5,000 to 9,000 MTPA at Tarapur to target 20–25% global share, leveraging a China+1 tailwind and multiple beverage and pharma customer contracts.
Listed peers in Pharmaceuticals: Jeena Sikho Lifecare Ltd, FDC Ltd, Supriya Lifescience Ltd, Senores Pharmaceuticals Ltd, Innova Captab Ltd, Bliss GVS Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹708.45 a share on 10 Jul 2026, Aarti Pharmalabs Ltd (AARTIPHARM) was valued at a price-to-earnings ratio of 34.45x against an industry P/E of 36.41x and a price-to-book of 3.23x on a book value of ₹219.44 per share as of Mar 2025. Solomo computes return on equity of 9.37% and return on capital employed of 12.3% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 34.45x
- Industry P/E
- 36.41x
- P/B
- 3.23x
- EPS (TTM)
- ₹20.57
- Book value / share
- ₹219.44
- ROE
- 9.37%
- ROCE
- 12.3%
- ROA
- 6.42%
- Debt / equity
- 0.21x
- Dividend yield
- 0.56%
- EBITDA margin
- 21.98%
- 52-week range
- ₹583.85 – ₹971.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aarti Pharmalabs Ltd (AARTIPHARM) reported revenue of ₹1,819 crore, net profit of ₹175 crore and earnings per share of ₹19.27. That compares with revenue of ₹2,115 crore and net profit of ₹272 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹583 crore and net profit ₹61 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 |
| Net profit (₹ cr) | 122 | 193 | 217 | 272 | 175 |
| EPS (₹) | - | 21.35 | 23.93 | 30.05 | 19.27 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 23.47% | 14.17% |
| Profit growth | 34.10% | 25.59% |
| Stock price CAGR | 30% | -26% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 42.86% of Aarti Pharmalabs Ltd (AARTIPHARM) (down 0.22 pp QoQ), foreign institutional investors (FII) hold 8.17% and domestic institutional investors (DII) hold 7.22%. Promoters have pledged 11.1% of their holding. Market capitalisation was ₹6,424 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2023.
Largest disclosed public shareholders in Jun 2026: Life Insurance Corporation Of India 5.27%, Ntasain Discovery Master Fund 2.16%, Nishant Pradip Shah 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 42.86% | 11.1% | 8.17% | 7.22% | 57.14% |
| Mar 2026 | 43.08% | 11% | 8.39% | 7.41% | 56.92% |
| Dec 2025 | 43.1% | - | 7.68% | 7.66% | 56.9% |
| Sep 2025 | 42.88% | - | 8.02% | 6.96% | 57.12% |
| Jun 2025 | 43.72% | - | 7.35% | 7.79% | 56.28% |
| Mar 2025 | 44.29% | - | 7.36% | 7.53% | 55.71% |
| Dec 2024 | 44.66% | - | 8.64% | 10.36% | 55.34% |
| Sep 2024 | 46.1% | - | 7.38% | 11.35% | 53.9% |